抗精神病药物与糖稳态失调:系统综述与荟萃分析
该系统综述与荟萃分析纳入127项随机对照试验,比较抗精神病药物与对照组对糖稳态参数的影响,发现抗精神病药物使用与空腹血糖、空腹胰岛素、糖化血红蛋白及高血糖风险显著升高相关,且该关联独立于用药时间、剂量、诊断及体重增加倾向。
要点
- 抗精神病药物使用显著升高空腹血糖、空腹胰岛素、糖化血红蛋白及高血糖风险。
- 糖稳态失调独立于用药时间、剂量、诊断及体重增加倾向。
- 建议加强代谢监测并考虑相应治疗。
核心结论
- 抗精神病药物暴露显著扰乱糖稳态,且独立于暴露时间、剂量、诊断及体重增加倾向。
- 建议提高对抗精神病药物所致糖稳态失调的认识,并进行持续代谢监测和潜在治疗。
研究设计与样本
- 系统综述与荟萃分析,检索MEDLINE、Embase、PsychINFO、CINAHL、CENTRAL和Web of Science自建库至2025年2月3日。
- 纳入比较抗精神病药物与对照组(安慰剂或无干预)糖稳态参数变化的盲法随机对照试验,最终127项研究进入荟萃分析。
主要发现
- 抗精神病药物使用与空腹血糖显著升高相关(平均差0.72 mg/dL;95%CI 0.54-1.08;P<.001)。
- 抗精神病药物使用与空腹胰岛素显著升高相关(平均差1.94 μIU/mL;95%CI 1.28-2.61;P<.001)。
- 抗精神病药物使用与糖化血红蛋白显著升高相关(平均差0.04%;95%CI 0.02%-0.05%;P<.001)。
- 抗精神病药物使用与高血糖风险显著升高相关(比值比1.29;95%CI 1.04-1.59;P=.02)。
- 在健康志愿者中结果得到佐证;亚组分析提示抗精神病药物类型、诊断、年龄、合并用药及既往暴露不持续影响糖代谢异常风险。
临床怎么用
- 临床应提高对抗精神病药物所致糖稳态失调的认识,并持续进行代谢监测。
- 考虑对已出现糖稳态失调的患者进行潜在治疗。
局限性
- 研究仅纳入英文文献。
- 亚组分析提示部分因素(如药物类型、诊断、年龄、合并用药、既往暴露)对糖代谢异常风险的影响不一致。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Antipsychotic drug (AP)-induced glucose homeostasis changes are often attributed to AP-induced weight gain. Nevertheless, dysregulated glucose control can occur independently of weight gain. OBJECTIVE: To examine the association between AP use and glucose homeostasis while considering weight gain propensity, medication type, and treatment duration. DATA SOURCES: MEDLINE, Embase, PsychINFO, CINAHL, the Cochrane Central Register of Controlled Trials (CENTRAL), and Web of Science were searched from inception through February 3, 2025. STUDY SELECTION: Blinded randomized clinical trials (RCTs) comparing changes in glucose homeostasis-related parameters between patients with severe mental illness or healthy volunteers assigned to AP or control (placebo or no intervention) groups were included. Studies were limited to English-language human studies without restrictions on study length, AP type, or previous AP exposure. Of 22 773 unique citations, 163 RCTs met inclusion criteria, with 127 studies included in the meta-analysis. DATA EXTRACTION AND SYNTHESIS: Each article was screened independently by 2 authors using predefined inclusion and exclusion criteria. Data extraction and risk of bias assessment were completed using a standardized spreadsheet. Data were analyzed via random-effects meta-analysis, with subgroup analyses for diagnosis, study length, AP type, age, concomitant medication use, and previous AP exposure. Metaregressions identified covariate effects. Data analysis was completed from October 2023 to February 2025. MAIN OUTCOMES AND MEASURES: Primary study outcomes were changes in fasting glucose, fasting insulin, and glycated hemoglobin (HbA1c) following AP treatment. Secondary outcomes included any other glucose metabolism-related parameters including, but not limited to, insulin resistance and hyperglycemia. RESULTS: A total of 35 952 AP-treated patients and 19 010 placebo-treated patients were included in the qualitative synthesis, while 28 975 AP-treated and 15 101 placebo-treated patients were included in the meta-analysis. AP use was associated with significantly increased fasting glucose (mean difference [MD], 0.72 mg/dL; 95% CI, 0.54-1.08 [to convert to millimoles per liter, multiply by 0.0555]; P < .001), fasting insulin (MD, 1.94 μIU/mL; 95% CI, 1.28-2.61 [to convert to picomoles per liter, multiply by 6]; P < .001), glycated hemoglobin (MD, 0.04%; 95% CI, 0.02%-0.05% [to convert to proportion of total hemoglobin, multiply by 0.01]; P < .001), and hyperglycemia (odds ratio, 1.29; 95% CI, 1.04-1.59; P = .02) vs placebo. Findings were corroborated in healthy volunteers. Subgroup analyses suggested that AP type, diagnosis, age, concomitant medication use, and previous AP exposure do not consistently affect dysglycemia risk. In metaregression analyses, AP-associated dysregulations in glucose homeostasis were independent of study length and AP dose. CONCLUSIONS AND RELEVANCE: In this systematic review and meta-analysis, results indicate that AP exposure significantly disrupts glucose homeostasis independent of exposure time, dose, diagnosis, and weight gain propensity. Increased awareness of AP-induced dysregulations in glucose homeostasis alongside ongoing metabolic monitoring and potential treatment is warranted.
引用
- Smith ECC, Agarwal SM, Panganiban KJ, et al. Antipsychotic Drugs and Dysregulated Glucose Homeostasis: A Systematic Review and Meta-Analysis. JAMA Psychiatry. 2025. PMID: 40864439. doi:10.1001/jamapsychiatry.2025.2240
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。